Generation Bio Co. Statistics
Total Valuation
GBIO has a market cap or net worth of $20.14 million. The enterprise value is -$49.84 million.
Important Dates
The next estimated earnings date is Wednesday, August 6, 2025, after market close.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GBIO has 67.04 million shares outstanding. The number of shares has increased by 1.11% in one year.
| Current Share Class | 67.04M |
| Shares Outstanding | 67.04M |
| Shares Change (YoY) | +1.11% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 5.55% |
| Owned by Institutions (%) | 59.98% |
| Float | 49.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.98 |
| Forward PS | 2.60 |
| PB Ratio | 0.33 |
| P/TBV Ratio | 0.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.43, with a Debt / Equity ratio of 1.19.
| Current Ratio | 8.43 |
| Quick Ratio | 8.11 |
| Debt / Equity | 1.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -70.06% and return on invested capital (ROIC) is -23.77%.
| Return on Equity (ROE) | -70.06% |
| Return on Assets (ROA) | -18.97% |
| Return on Invested Capital (ROIC) | -23.77% |
| Return on Capital Employed (ROCE) | -40.69% |
| Revenue Per Employee | $213,530 |
| Profits Per Employee | -$625,470 |
| Employee Count | 115 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.27% in the last 52 weeks. The beta is 2.66, so GBIO's price volatility has been higher than the market average.
| Beta (5Y) | 2.66 |
| 52-Week Price Change | -89.27% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 1.09 |
| Relative Strength Index (RSI) | 35.48 |
| Average Volume (20 Days) | 907,113 |
Short Selling Information
The latest short interest is 1.88 million, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 1.88M |
| Short Previous Month | 1.09M |
| Short % of Shares Out | 2.81% |
| Short % of Float | 3.83% |
| Short Ratio (days to cover) | 3.76 |
Income Statement
In the last 12 months, GBIO had revenue of $24.56 million and -$71.93 million in losses. Loss per share was -$1.08.
| Revenue | 24.56M |
| Gross Profit | -24.16M |
| Operating Income | -73.96M |
| Pretax Income | -158.43M |
| Net Income | -71.93M |
| EBITDA | -69.20M |
| EBIT | -73.96M |
| Loss Per Share | -$1.08 |
Full Income StatementBalance Sheet
The company has $157.56 million in cash and $87.58 million in debt, giving a net cash position of $69.98 million or $1.04 per share.
| Cash & Cash Equivalents | 157.56M |
| Total Debt | 87.58M |
| Net Cash | 69.98M |
| Net Cash Per Share | $1.04 |
| Equity (Book Value) | 73.33M |
| Book Value Per Share | 1.09 |
| Working Capital | 145.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$85.23 million and capital expenditures -$729,000, giving a free cash flow of -$85.96 million.
| Operating Cash Flow | -85.23M |
| Capital Expenditures | -729,000 |
| Free Cash Flow | -85.96M |
| FCF Per Share | -$1.28 |
Full Cash Flow StatementMargins
Gross margin is -98.38%, with operating and profit margins of -301.18% and -292.92%.
| Gross Margin | -98.38% |
| Operating Margin | -301.18% |
| Pretax Margin | -292.92% |
| Profit Margin | -292.92% |
| EBITDA Margin | -281.81% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.11% |
| Shareholder Yield | -1.11% |
| Earnings Yield | -357.19% |
| FCF Yield | -426.84% |
Analyst Forecast
The average price target for GBIO is $7.33, which is 2,340.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.33 |
| Price Target Difference | 2,340.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 10.73% |
| EPS Growth Forecast (5Y) | -18.89% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GBIO has an Altman Z-Score of -4.55 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.55 |
| Piotroski F-Score | 3 |